{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:12:08Z","timestamp":1780071128279,"version":"3.54.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106698"],"award-info":[{"award-number":["106698"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["102975"],"award-info":[{"award-number":["102975"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["077092"],"award-info":[{"award-number":["077092"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.vaccine.2016.10.073","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T20:30:29Z","timestamp":1480537829000},"page":"403-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach"],"prefix":"10.1016","volume":"35","author":[{"given":"Wirichada","family":"Pan-Ngum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Kinyanjui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Kiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sompob","family":"Saralamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Van Effelterre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. James","family":"Nokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.10.073_b0005","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.10.073_b0010","unstructured":"PATH. RSV vaccine snapshot; 2015."},{"key":"10.1016\/j.vaccine.2016.10.073_b0015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1017\/S0950268804003450","article-title":"The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection","volume":"133","author":"White","year":"2005","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.10.073_b0020","doi-asserted-by":"crossref","first-page":"e0138018","DOI":"10.1371\/journal.pone.0138018","article-title":"Vaccine induced herd immunity for control of respiratory syncytial virus disease in a low-income country setting","volume":"10","author":"Kinyanjui","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.10.073_b0025","doi-asserted-by":"crossref","first-page":"e42320","DOI":"10.1371\/journal.pone.0042320","article-title":"Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models","volume":"7","author":"Pitzer","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.10.073_b0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","article-title":"Public health impact and cost-effectiveness of the RTS, S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models","volume":"387","author":"Penny","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.10.073_b0035","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1016\/j.vaccine.2010.05.056","article-title":"Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis","volume":"28","author":"Van de Velde","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.073_b0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0025-5564(01)00066-9","article-title":"Modeling epidemics caused by respiratory syncytial virus (RSV)","volume":"172","author":"Weber","year":"2001","journal-title":"Math Biosci"},{"key":"10.1016\/j.vaccine.2016.10.073_b0045","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.mbs.2006.08.018","article-title":"Understanding the transmission dynamics of respiratory syncytial virus using multiple time series and nested models","volume":"209","author":"White","year":"2006","journal-title":"Math Biosci"},{"key":"10.1016\/j.vaccine.2016.10.073_b0050","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/ije\/dys062","article-title":"Profile: the Kilifi health and demographic surveillance system (KHDSS)","volume":"41","author":"Scott","year":"2012","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.10.073_b0055","doi-asserted-by":"crossref","first-page":"e104786","DOI":"10.1371\/journal.pone.0104786","article-title":"Quantifying age-related rates of social contact using diaries in a rural coastal population of Kenya","volume":"9","author":"Kiti","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.10.073_b0060","series-title":"Infectious diseases of humans: dynamics and control","author":"Anderson","year":"1991"},{"key":"10.1016\/j.vaccine.2016.10.073_b0065","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1086\/606055","article-title":"Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance","volume":"49","author":"Nokes","year":"2009","journal-title":"Clin Infect Diseases Official Publ Infectious Diseases Soc Am"},{"key":"10.1016\/j.vaccine.2016.10.073_b0070","doi-asserted-by":"crossref","first-page":"300ra127","DOI":"10.1126\/scitranslmed.aac5757","article-title":"Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections","volume":"7","author":"Taylor","year":"2015","journal-title":"Sci Trans Med"},{"key":"10.1016\/j.vaccine.2016.10.073_b0075","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/mtm.2015.18","article-title":"Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates","volume":"2","author":"Pierantoni","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.vaccine.2016.10.073_b0080","doi-asserted-by":"crossref","first-page":"13418","DOI":"10.1128\/JVI.01219-14","article-title":"Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques","volume":"88","author":"Florek","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.10.073_b0085","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.vaccine.2009.02.061","article-title":"DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial","volume":"27","author":"Jones","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.073_b0090","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0264-410X(97)00003-0","article-title":"Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period","volume":"15","author":"Keitel","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.073_b0095","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1128\/AAC.00761-15","article-title":"GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein","volume":"59","author":"Samuel","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2016.10.073_b0100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1401184","article-title":"Oral GS-5806 activity in a respiratory syncytial virus challenge study","volume":"371","author":"DeVincenzo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.073_b0105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/irv.12245","article-title":"Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines","volume":"8","author":"van Essen","year":"2014","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2016.10.073_b0110","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/infdis\/169.6.1368","article-title":"Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin","volume":"169","author":"Siber","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.073_b0115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV study group","volume":"102","author":"Group TI-RS","year":"1998","journal-title":"Pediatrics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16310234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16310234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:23:45Z","timestamp":1759400625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16310234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0264410X16310234"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}